{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:16:43Z","timestamp":1791062203288,"version":"4.1.0"},"reference-count":71,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,12,1]]},"abstract":"<jats:p>Pertussis re-emerged in Sweden with a cumulative incidence of about 60% during the first 10 years of life, when the locally produced cellular vaccine lost its efficacy around 1970 and general vaccination was discontinued in 1979. The epidemiology, clinical features, and immunology of pertussis and a monocomponent pertussis toxoid vaccine were studied in Go\u0308teborg, Sweden.<\/jats:p><jats:p>After phase 1 and 2 studies, a randomized, double-blind, placebo-controlled trial of pertussis toxoid (PTox), compounded with diphtheria and tetanus toxoids, was administered to 3450 children according to the Swedish schedule at 3, 5, and 12 months of age. After a mean follow-up of 18 months, the efficacy was 71% overall and 75% in household contacts, respectively. A statistically significant correlation was found between the level of PTox-induced antibodies and protection against pertussis. As observed with cellular and with multicomponent acellular vaccines, PTox reduced the severity of disease and the percent of children with positive cultures. Furthermore, vaccination reduced the transmission of Bordetella pertussis to household contacts in the vaccinees compared with the controls who received only diphtheria and tetanus toxoids. Patients with culture-verified Bordetella parapertussis infection reacted with antibodies to pertactin and to filamentous hemagglutinin but not to pertussis toxin, and some subsequently developed pertussis. The antibody responses of patients with pertussis to the surface polysaccharides of B pertussis and to B parapertussis were cross-reactive serologically. Serosurveys showed that only antibodies to pertussis toxin were related to the occurrence of pertussis in the general population: antibodies to filamentous hemagglutinin and pertactin were probably stimulated by antigens of other bacteria as well as Bordetellae.<\/jats:p><jats:p>Mass vaccination of Go\u0308teborg children born in the 1990s was started in 1995. In February 1999, about 55% had been vaccinated and both B pertussis and pertussis decreased significantly in individuals of all ages (herd immunity). Similar to diphtheria, PTox-induced immunity to pertussis occurs both on an individual and community basis.<\/jats:p><jats:p>The apparent greater efficacy of multicomponent acellular pertussis vaccines compared with monocomponent PTox was proposed to be an artifact created when the diagnosis of pertussis was made by the serologic criteria of the World Health Organization only. Our conclusion is that PTox is both an essential and alone sufficient antigen in acellular pertussis vaccines.<\/jats:p>","DOI":"10.1542\/peds.108.6.e115","type":"journal-article","created":{"date-parts":[[2004,8,13]],"date-time":"2004-08-13T23:55:51Z","timestamp":1092441351000},"page":"e115-e115","source":"Crossref","is-referenced-by-count":27,"title":["Immunologic and Epidemiologic Experience of Vaccination With a Monocomponent Pertussis Toxoid Vaccine"],"prefix":"10.1542","volume":"108","author":[{"given":"John","family":"Taranger","sequence":"first","affiliation":[{"name":"Go\u0308teborg Pertussis Vaccine Study, Go\u0308teborg Primary Health Care, Go\u0308teborg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birger","family":"Trollfors","sequence":"additional","affiliation":[{"name":"Go\u0308teborg Pertussis Vaccine Study, Go\u0308teborg Primary Health Care, Go\u0308teborg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Bergfors","sequence":"additional","affiliation":[{"name":"Go\u0308teborg Pertussis Vaccine Study, Go\u0308teborg Primary Health Care, Go\u0308teborg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Knutsson","sequence":"additional","affiliation":[{"name":"Go\u0308teborg Pertussis Vaccine Study, Go\u0308teborg Primary Health Care, Go\u0308teborg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Lagerga\u030ard","sequence":"additional","affiliation":[{"name":"Go\u0308teborg Pertussis Vaccine Study, Go\u0308teborg Primary Health Care, Go\u0308teborg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Schneerson","sequence":"additional","affiliation":[{"name":"National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Robbins","sequence":"additional","affiliation":[{"name":"National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2001,12,1]]},"reference":[{"key":"2021121003492444100_R1","unstructured":"Rabo E. The recurrence of pertussis [in Swedish]. Lakartidningen.1975;72:2036\u20132038"},{"key":"2021121003492444100_R2","doi-asserted-by":"crossref","unstructured":"Pittman M. Pertussis toxin: the cause of the harmful effects and prolonged immunity of whooping cough. A hypothesis. Rev Infect Dis.1979;1:401\u2013412","DOI":"10.1093\/clinids\/1.3.401"},{"key":"2021121003492444100_R3","unstructured":"Robbins JB. Towards a New Vaccine for Pertussis: Microbiology 1984. Washington, DC: American Society for Microbiology; 1984:176\u2013183"},{"key":"2021121003492444100_R4","doi-asserted-by":"crossref","unstructured":"Sekura R, Zhang Y-L, Roberson R, et al. Clinical, metabolic, and antibody responses of adult volunteers to an investigational vaccine composed of pertussis toxin inactivated by hydrogen peroxide. J Pediatr.1988;113:806\u2013813","DOI":"10.1016\/S0022-3476(88)80005-2"},{"key":"2021121003492444100_R5","doi-asserted-by":"crossref","unstructured":"Krantz I, Sekura R, Trollfors B, et al. Immunogenicity and safety of a pertussis vaccine composed of pertussis toxin inactivated by hydrogen peroxide in 18- to 23-month-old children. J Pediatr.1990;116:539\u2013543","DOI":"10.1016\/S0022-3476(05)81599-9"},{"key":"2021121003492444100_R6","doi-asserted-by":"crossref","unstructured":"Siber G, Thakrar N, Yancey BA, et al. Safety and immunogenicity of hydrogen peroxide-inactivated pertussis toxoid in 18-month-old children. Vaccine.1991;9:735\u2013740","DOI":"10.1016\/0264-410X(91)90289-I"},{"key":"2021121003492444100_R7","doi-asserted-by":"crossref","unstructured":"Isacson J, Trollfors B, Taranger J, et al. Safety, immunogenicity and an open, retrospective study of efficacy of a monocomponent pertussis toxoid vaccine in infants. Pediatr Infect Dis J.1994;13:22\u201327","DOI":"10.1097\/00006454-199401000-00006"},{"key":"2021121003492444100_R8","doi-asserted-by":"crossref","unstructured":"Trollfors B, Taranger J, Lagerga\u030ard T, et al. A placebo-controlled trial of a pertussis toxoid vaccine. N Engl J Med.1995;333:1045\u20131050","DOI":"10.1056\/NEJM199510193331604"},{"key":"2021121003492444100_R9","unstructured":"WHO Meeting on Case Definitions of Pertussis. Geneva, Switzerland: World Health Organization; 1991;MIM\/EPI\/PERT\/91.1:10\u201311"},{"key":"2021121003492444100_R10","doi-asserted-by":"crossref","unstructured":"Taranger J, Trollfors B, Lagerga\u030ard T, et al. Unchanged efficacy of a pertussis toxoid vaccine throughout the two years after the third vaccination of infants. Pediatr Infect Dis J.1997;16:180\u2013184","DOI":"10.1097\/00006454-199702000-00003"},{"key":"2021121003492444100_R11","doi-asserted-by":"crossref","unstructured":"Robbins JB, Pittman M, Trollfors B, Lagerga\u030ard T, Taranger J, Schneerson R. Primum non nocere: a pharmacologically inert pertussis toxoid alone should be the next pertussis vaccine. Pediatr Infect Dis J.1993;12:795\u2013807","DOI":"10.1097\/00006454-199310000-00001"},{"key":"2021121003492444100_R12","doi-asserted-by":"crossref","unstructured":"Schneerson R, Robbins JB, Taranger J, Lagerga\u030ard T, Trollfors B. A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned. Lancet.1996;348:1289\u20131292","DOI":"10.1016\/S0140-6736(96)05243-9"},{"key":"2021121003492444100_R13","doi-asserted-by":"crossref","unstructured":"Trollfors B, Taranger J, Lagerga\u030ard T, et al. Efficacy of a monocomponent pertussis toxoid vaccine after household exposure to pertussis. J Pediatr.1997;130:532\u2013536","DOI":"10.1016\/S0022-3476(97)70234-8"},{"key":"2021121003492444100_R14","doi-asserted-by":"crossref","unstructured":"Fine PE, Clarkson JA, Miller E. The efficacy of pertussis vaccines under conditions of household exposure. Further analysis of the 1978\u201380 PHLS\/ERL study in 21 area health authorities in England. Int J Epidemiol.1988;17:635\u2013642","DOI":"10.1093\/ije\/17.3.635"},{"key":"2021121003492444100_R15","doi-asserted-by":"crossref","unstructured":"Onorato IM, Wassilak SG, Meade B. Efficacy of whole-cell pertussis vaccine in preschool children in the United States. JAMA.1992;267:2745\u20132849","DOI":"10.1001\/jama.1992.03480200053023"},{"key":"2021121003492444100_R16","doi-asserted-by":"crossref","unstructured":"Storsaeter J, Blackwelder WC, Hallander HO. Pertussis antibodies, protection, and vaccine efficacy after household exposure. Am J Dis Child.1992;146:167\u2013172","DOI":"10.1001\/archpedi.1992.02160140033016"},{"key":"2021121003492444100_R17","doi-asserted-by":"crossref","unstructured":"Schmitt HJ, von Konig CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA.1996;275:37\u201341","DOI":"10.1001\/jama.275.1.37"},{"key":"2021121003492444100_R18","doi-asserted-by":"crossref","unstructured":"Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis.Vaccine.1998;16:1907\u20131916","DOI":"10.1016\/S0264-410X(98)00227-8"},{"key":"2021121003492444100_R19","doi-asserted-by":"crossref","unstructured":"Heininger U, Cherry JD, Stehr K, et al. Comparative efficacy of the Lederle\/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group. Pediatrics.1998;102:546\u2013553","DOI":"10.1542\/peds.102.3.546"},{"key":"2021121003492444100_R20","doi-asserted-by":"crossref","unstructured":"Trollfors B, Taranger J, Lagerga\u030ard T, et al. Immunization of children with pertussis toxoid decreases spread of pertussis within the family. Pediatr Infect Dis J.1998;17:196\u2013199","DOI":"10.1097\/00006454-199803000-00005"},{"key":"2021121003492444100_R21","doi-asserted-by":"crossref","unstructured":"Taranger J, Trollfors B, Lagerga\u030ard T, Zackrisson G. Parapertussis infection followed by pertussis infection. Lancet.1994;344:1703","DOI":"10.1016\/S0140-6736(94)90485-5"},{"key":"2021121003492444100_R22","doi-asserted-by":"crossref","unstructured":"Bergfors E, Trollfors B, Taranger J, Lagerga\u030ard T, Sundh V, Zackrisson G. Parapertussis and pertussis: differences and similarities in incidence, clinical course, and antibody responses. Int J Infect Dis.1999;3:140\u2013146","DOI":"10.1016\/S1201-9712(99)90035-8"},{"key":"2021121003492444100_R23","doi-asserted-by":"crossref","unstructured":"Heininger U, Stehr K, Schmitt-Grohe S, et al. Clinical characteristics of illness caused by Bordetella parapertussis compared with illness caused by Bordetella pertussis.Pediatr Infect Dis J.1994;13:306\u2013309","DOI":"10.1097\/00006454-199404000-00011"},{"key":"2021121003492444100_R24","doi-asserted-by":"crossref","unstructured":"Locht C, Keith JM. Pertussis toxin gene: nucleotide sequence and genetic organisation. Science.1986;232:1258\u20131264","DOI":"10.1126\/science.3704651"},{"key":"2021121003492444100_R25","doi-asserted-by":"crossref","unstructured":"Marchitto KS, Smith SG, Locht C, Keith JM. Nucleotide sequence homology to pertussis toxin gene in Bordetella bronchiseptica and Bordetella parapertussis.Infect Immun.1987;55:497\u2013501","DOI":"10.1128\/iai.55.3.497-501.1987"},{"key":"2021121003492444100_R26","doi-asserted-by":"crossref","unstructured":"Nicosia A, Perugini M, Franzini C, et al. Cloning and sequence of the pertussis toxin genes: Operon structure and gene duplication. Proc Natl Acad Sci U. S. A.1986;83:4631\u20134635","DOI":"10.1073\/pnas.83.13.4631"},{"key":"2021121003492444100_R27","doi-asserted-by":"crossref","unstructured":"Arico B, Rappuoli R. Bordetella parapertussis and Bordetella bronchiseptica contain transcriptionally silent pertussis toxin genes. J Bacteriol.1987;169:2847\u20132853","DOI":"10.1128\/jb.169.6.2847-2853.1987"},{"key":"2021121003492444100_R28","doi-asserted-by":"crossref","unstructured":"Kendrick PL, Nadolski EB, Eldering G, Baker J. Antigenic relationships of Haemophilus pertussis, the parapertussis bacillus, and Brucella bronchiseptica as shown by cross protection tests in mice. J Bacteriol.1953;66:166\u2013169","DOI":"10.1128\/jb.66.2.166-169.1953"},{"key":"2021121003492444100_R29","doi-asserted-by":"crossref","unstructured":"Khelef N, Danve B, Quentin-Millet M-J, Guiso N. Bordetella pertussis and Bordetella parapertussis: two immunologically distinct species. Infect Immun.1993;61:486\u2013490","DOI":"10.1128\/iai.61.2.486-490.1993"},{"key":"2021121003492444100_R30","doi-asserted-by":"crossref","unstructured":"DiFabio JL, Caroff M, Karibian D, Richards JC, Perry MB. Characterization of the common antigenic lipopolysaccharide O-chains produced by Bordetella bronchiseptica and Bordetella parapertussis.FEMS Microbiol Lett.1992;76:275\u2013281","DOI":"10.1111\/j.1574-6968.1992.tb05475.x"},{"key":"2021121003492444100_R31","doi-asserted-by":"crossref","unstructured":"Trollfors N, Lagerga\u030ard T, Taranger J, Bergfors E, Schneerson R, Robbins JB. Serum IgG antibody responses to the lipooligosaccharide of Bordetella pertussis and the lipolysaccharide of Bordetella parapertussis in children with pertussis and parapertussis. Clin Diagn Lab Immunol.2001;8:1015\u20131017","DOI":"10.1128\/CDLI.8.5.1015-1017.2001"},{"key":"2021121003492444100_R32","doi-asserted-by":"crossref","unstructured":"Robbins JB, Chu C, Schneerson R. Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal Salmonellae and Shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides. Clin Infect Dis.1992;15:346\u2013361","DOI":"10.1093\/clinids\/15.2.346"},{"key":"2021121003492444100_R33","doi-asserted-by":"crossref","unstructured":"Granstro\u0308m G, Wretlind B, Salenstedt C-R, Granstro\u0308m M. Evaluation of serologic assays for diagnosis of whooping cough. J Clin Microbiol.1988;26:1818\u20131823","DOI":"10.1128\/jcm.26.9.1818-1823.1988"},{"key":"2021121003492444100_R34","doi-asserted-by":"crossref","unstructured":"Zackrisson G, Taranger J, Trollfors B. History of whooping cough in nonvaccinated Swedish children, related to serum antibodies to pertussis toxin and filamentous hemagglutinin. J Pediatr.1990;116:190\u2013194","DOI":"10.1016\/S0022-3476(05)82873-2"},{"key":"2021121003492444100_R35","doi-asserted-by":"crossref","unstructured":"Granstro\u0308m M, Granstro\u0308m G. Serological correlates in whooping cough. Vaccine.1993;11:445\u2013448","DOI":"10.1016\/0264-410X(93)90286-7"},{"key":"2021121003492444100_R36","doi-asserted-by":"crossref","unstructured":"Taranger J, Trollfors B, Lagerga\u030ard T, et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis.2000;181:1010\u20131013","DOI":"10.1086\/315318"},{"key":"2021121003492444100_R37","unstructured":"Robbins JB, Schneerson R, Trollfors B, Taranger J, Lagerga\u030ard T. Standardization of acellular pertussis vaccine by assay of serum neutralizing antibodies to pertussis toxin (antitoxin): analogy with diphtheria toxoid. Dev Biol Stand.1998;95:155\u2013158"},{"key":"2021121003492444100_R38","doi-asserted-by":"crossref","unstructured":"Trollfors B, Taranger J, Lagerga\u030ard T, et al. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis. Clin Infect Dis.1999;28:552\u2013559","DOI":"10.1086\/515172"},{"key":"2021121003492444100_R39","doi-asserted-by":"crossref","unstructured":"Trollfors B, Zackrisson G, Taranger J, Lagerga\u030ard T. Serum antibodies against a 69-kilodalton outer-membrane protein, pertactin, from Bordetella pertussis in nonvaccinated children with and without a history of clinical pertussis. J Pediatr.1992;120:924\u2013926","DOI":"10.1016\/S0022-3476(05)81963-8"},{"key":"2021121003492444100_R40","doi-asserted-by":"crossref","unstructured":"Isacson J, Trollfors B, Hedvall G, Taranger J, Zackrisson G. Response and decline of serum IgG antibodies to pertussis toxin, filamentous hemagglutinin and pertactin in children with pertussis. Scand J Infect Dis.1995;27:273\u2013277","DOI":"10.3109\/00365549509019021"},{"key":"2021121003492444100_R41","doi-asserted-by":"crossref","unstructured":"Isacson J, Trollfors B, Taranger J, Lagerga\u030ard T. Acquisition of IgG serum antibodies against two Bordetella antigens (filamentous hemagglutinin and pertactin) in children with no symptoms of pertussis. Pediatr Infect Dis J.1995;14:517\u2013521","DOI":"10.1097\/00006454-199506000-00009"},{"key":"2021121003492444100_R42","doi-asserted-by":"crossref","unstructured":"Carlsson R-M, Claesson BA, Lagerga\u030ard T, Trollfors B. Acquisition of serum antibodies unrelated to Bordetella pertussis infection. Clin Microbiol Infect.1999;5:709\u2013712","DOI":"10.1111\/j.1469-0691.1999.tb00520.x"},{"key":"2021121003492444100_R43","doi-asserted-by":"crossref","unstructured":"Barenkamp SJ, Leininger E. Cloning, expression and DNA sequence analysis of genes encoding nontypeable Haemophilus influenzae high-molecular-weight surface-exposed proteins related to filamentous hemagglutinin of Bordetella pertussis.Infect Immun.1992;60:1302\u20131313","DOI":"10.1128\/iai.60.4.1302-1313.1992"},{"key":"2021121003492444100_R44","doi-asserted-by":"crossref","unstructured":"Taranger J, Trollfors B, Bergfors E, et al. Mass vaccination of children with pertussis toxoid\u2014decreased incidence in both vaccinated and nonvaccinated individuals. Clin Infect Dis.2001;33:1004\u20131010","DOI":"10.1086\/322639"},{"key":"2021121003492444100_R45","doi-asserted-by":"crossref","unstructured":"Storsaeter J, Hallander H, Farrington CP, Olin P, Mo\u0308llby R, Miller E. Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial. Vaccine.1990;8:457\u2013461","DOI":"10.1016\/0264-410X(90)90246-I"},{"key":"2021121003492444100_R46","doi-asserted-by":"crossref","unstructured":"Blackwelder WC, Storsaeter J, Olin P, Hallander HO. Acellular pertussis vaccines: efficacy and evaluation of clinical case definitions. Am J Dis Child.1991;145:1285\u20131289","DOI":"10.1001\/archpedi.1991.02160110077024"},{"key":"2021121003492444100_R47","doi-asserted-by":"crossref","unstructured":"Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med.1996;334:349\u2013355","DOI":"10.1056\/NEJM199602083340602"},{"key":"2021121003492444100_R48","doi-asserted-by":"crossref","unstructured":"Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med.1996;334:341\u2013348","DOI":"10.1056\/NEJM199602083340601"},{"key":"2021121003492444100_R49","doi-asserted-by":"crossref","unstructured":"Public Health Service Laboratory Epidemiological Research Laboratory and 21 health authorities. Efficacy of pertussis vaccination in England. BMJ.1982;285:357\u2013359","DOI":"10.1136\/bmj.285.6338.357"},{"key":"2021121003492444100_R50","doi-asserted-by":"crossref","unstructured":"Kwantes W, Joynson DHM, Williams WO. Bordetella pertussis isolation in general practice: 1977\u201379 whooping cough epidemic in West Glamorgan. J Hyg Camb.1983;:90:149\u2013158","DOI":"10.1017\/S0022172400028825"},{"key":"2021121003492444100_R51","doi-asserted-by":"crossref","unstructured":"Grob PR, Crowder MJ, Robbins JF. Effect of vaccination on severity and dissemination of whooping cough. BMJ.1981;282:1925\u20131928","DOI":"10.1136\/bmj.282.6280.1925"},{"key":"2021121003492444100_R52","doi-asserted-by":"crossref","unstructured":"Jenkinson D. Natural course of 500 consecutive cases of whooping cough: a general practice population. BMJ.1995;310:299\u20133026","DOI":"10.1136\/bmj.310.6975.299"},{"key":"2021121003492444100_R53","doi-asserted-by":"crossref","unstructured":"Ad Hoc Group for the Study of Pertussis Vaccines. Placebo-controlled trial of two acellular pertussis vaccines in Sweden: protective efficacy and adverse events. Lancet.1988;i:955\u2013960","DOI":"10.1016\/S0140-6736(88)91778-3"},{"key":"2021121003492444100_R54","doi-asserted-by":"crossref","unstructured":"Liese JG, Meschievitz CK, Harzer E, et al. Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr Infect Dis J.1997;16:1038\u20131044","DOI":"10.1097\/00006454-199711000-00007"},{"key":"2021121003492444100_R55","doi-asserted-by":"crossref","unstructured":"Schneerson R, Robbins JB, Taranger J, Trollfors B, Lagerga\u030ard T. Author\u2019s reply. Lancet.1997;347:137\u2013138","DOI":"10.1016\/S0140-6736(05)60928-2"},{"key":"2021121003492444100_R56","doi-asserted-by":"crossref","unstructured":"Cherry JD, Olin P. The science and fiction of pertussis vaccine. Pediatrics.1999;104:1381\u20131383","DOI":"10.1542\/peds.104.6.1381"},{"key":"2021121003492444100_R57","doi-asserted-by":"crossref","unstructured":"Stehr K, Cherry JD, Heininger U, et al. A comparative efficacy trial in Germany in infants who received either the Lederle\/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics.1998;101:1\u201311","DOI":"10.1542\/peds.101.1.1"},{"key":"2021121003492444100_R58","doi-asserted-by":"crossref","unstructured":"Sato H, Sato Y. Experience with diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine in Japan. Clin Infect Dis.1999;28:S124\u2013S130","DOI":"10.1086\/515063"},{"key":"2021121003492444100_R59","doi-asserted-by":"crossref","unstructured":"Linneman CC, EB Perry. Bordetella parapertussis. Recent experience and review of the literature. Am J Dis Child.1977;1331:560\u2013563","DOI":"10.1001\/archpedi.1977.02120180074014"},{"key":"2021121003492444100_R60","doi-asserted-by":"crossref","unstructured":"Mertsola J. Mixed outbreak of Bordetella pertussis and Bordetella parapertussis infection in Finland. Eur J Clin Microbiol.1985;4:123\u2013128","DOI":"10.1007\/BF02013576"},{"key":"2021121003492444100_R61","unstructured":"Iwata S, Aoyama T, Goto A, et al. Mixed outbreak of Bordetella pertussis and Bordetella parapertussis in an apartment house. Dev Biol Stand.1991;73:333\u2013341"},{"key":"2021121003492444100_R62","doi-asserted-by":"crossref","unstructured":"Kawai H, Aoyama T, Murase Y, Tamura C, Imaizumi A. A causal relationship between Bordetella pertussis and Bordetella parapertussis infection. Scand J Infect Dis.1996;28:377\u2013381","DOI":"10.3109\/00365549609037923"},{"key":"2021121003492444100_R63","unstructured":"Meade BD, Kind PD, Manclark CR. Inhibition of murine macrophage migration by the leukocytosis-promoting toxin of Bordetella pertussis.Res J Reticulendothel Soc.1982;32:64\u201365"},{"key":"2021121003492444100_R64","doi-asserted-by":"crossref","unstructured":"Spangrude GJ, Sacchi F, Hill HR, Van Epps DE, Daynes RA. Inhibition of lymphocyte and neutrophil chemotaxis by pertussis toxin. J Immunol.1985;135:4135\u20134143","DOI":"10.4049\/jimmunol.135.6.4135"},{"key":"2021121003492444100_R65","doi-asserted-by":"crossref","unstructured":"Robbins JB. Pertussis in adults: introduction. Clin Infect Dis.1999;28:S91\u2013S93","DOI":"10.1086\/515054"},{"key":"2021121003492444100_R66","doi-asserted-by":"crossref","unstructured":"Schneerson R. Similarities between the pathogenesis of and immunity to diphtheria and pertussis: the complex nature of serum antitoxin-induced immunity to diphtheria to these two diseases. Clin Infect Dis.1999;28:S136\u2013S137","DOI":"10.1086\/515060"},{"key":"2021121003492444100_R67","doi-asserted-by":"crossref","unstructured":"Woods DE, Franklin R, Cryz SJ Jr, Ganss M, Peppler M, Ewanowich C. Development of a rat model for respiratory infection with Bordetella pertussis.Infect Immun.1989;57:1018\u20131024","DOI":"10.1128\/iai.57.4.1018-1024.1989"},{"key":"2021121003492444100_R68","doi-asserted-by":"crossref","unstructured":"Hall E, Parton R, Wardlaw AC. Cough production, leucocytosis and serology of rats infected intrabronchially with Bordetella pertussis.J Med Microbiol.1994;40:205\u2013213","DOI":"10.1099\/00222615-40-3-205"},{"key":"2021121003492444100_R69","doi-asserted-by":"crossref","unstructured":"Parton R, Hall E, Wardlaw AC. Responses to Bordetella pertussis mutant strains and to vaccination in the coughing rat model of pertussis. J Med Microbiol.1994;40:307\u2013312","DOI":"10.1099\/00222615-40-5-307"},{"key":"2021121003492444100_R70","doi-asserted-by":"crossref","unstructured":"Hall E, Parton R, Wardlaw AC. Responses to acellular pertussis vaccines and component antigens in a coughing-rat model of pertussis. Vaccine.1998;16:1595\u20131603","DOI":"10.1016\/S0264-410X(98)80001-7"},{"key":"2021121003492444100_R71","doi-asserted-by":"crossref","unstructured":"Kendrick P. Can whooping cough be eradicated?J Infect Dis.1975;132:707\u2013712","DOI":"10.1093\/infdis\/132.6.707"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/108\/6\/e115\/1113367\/pe120100e115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/108\/6\/e115\/1113367\/pe120100e115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T05:31:44Z","timestamp":1682746304000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/108\/6\/e115\/63615\/Immunologic-and-Epidemiologic-Experience-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12,1]]},"references-count":71,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2001,12,1]]},"published-print":{"date-parts":[[2001,12,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.108.6.e115","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,12,1]]}}}